---
title: "Shanghai RAAS: SR604 injection enters Phase IIb clinical trial research"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247616850.md"
description: "Shanghai RAAS announced that its SR604 injection has entered Phase IIb clinical trials, aimed at evaluating its safety, tolerability, and efficacy in patients with Hemophilia A/B and congenital factor VII deficiency. The injection is administered via subcutaneous injection and has completed Phase I and Phase IIa trials, supporting the initiation of Phase IIb trials, which plan to conduct multiple groups of trials with different dosing intervals"
datetime: "2025-07-08T10:11:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247616850.md)
  - [en](https://longbridge.com/en/news/247616850.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247616850.md)
generator: "portal-rs"
---

# Shanghai RAAS: SR604 injection enters Phase IIb clinical trial research

According to the announcement from Shanghai RAAS (002252.SZ), the company recently disclosed the registration information for a Phase IIb clinical trial on the National Medical Products Administration's drug clinical trial registration and information disclosure platform. The trial is titled: An open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, efficacy, and PK/PD characteristics of SR604 injection in patients with Hemophilia A/B and congenital factor VII deficiency.

As indicated in the announcement, SR604 injection is intended for the preventive treatment of bleeding in patients with Hemophilia A/B and congenital factor VII deficiency. SR604 is administered via subcutaneous injection to prevent and treat bleeding. The Part A dose-escalation Phase I trial (single-dose phase) has completed the enrollment and administration of subjects in 6 dose groups: 0.025mg/kg, 0.05mg/kg, 0.1mg/kg, 0.2mg/kg, 0.4mg/kg, and 0.8mg/kg; as well as the Part B efficacy exploration Phase IIa trial (multiple-dose phase) with 2 dose groups: 0.05mg/kg and 0.1mg/kg, with subjects receiving treatment once every two weeks for a total of 6 months. Existing safety and preliminary efficacy data support the initiation of the Part C efficacy exploration Phase IIb trial (multiple-dose phase), which will conduct a trial with a 0.4mg/kg dose group administered once every 4, 6, or 8 weeks for a total of 6 months

### Related Stocks

- [002252.CN](https://longbridge.com/en/quote/002252.CN.md)

## Related News & Research

- [Negative Link Announces Global Expansion and Next Phase of Growth](https://longbridge.com/en/news/296644416.md)
- [14:41 ETNine Corboy & Demetrio Attorneys selected to 2027 The Best Lawyers in America®](https://longbridge.com/en/news/296644470.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [FONDIA: Profitability improved sharply in H1 2026, driven by growth in Finland and the Baltics](https://longbridge.com/en/news/296439068.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**